Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.305 EUR -0.97% Market Closed
Market Cap: 32.7m EUR
Have any thoughts about
Gensight Biologics SA?
Write Note

Relative Value

The Relative Value of one SIGHT stock under the Base Case scenario is 0.361 EUR. Compared to the current market price of 0.305 EUR, Gensight Biologics SA is Undervalued by 16%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SIGHT Relative Value
Base Case
0.361 EUR
Undervaluation 16%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
73
vs Industry
29
Median 3Y
19.1
Median 5Y
28.5
Industry
8.1
Forward
8.7
vs History
vs Industry
Median 3Y
-1.4
Median 5Y
-3.4
Industry
23
Forward
-0.6
vs History
vs Industry
2
Median 3Y
-2.6
Median 5Y
-4.4
Industry
23.4
vs History
vs Industry
11
Median 3Y
-3.5
Median 5Y
-4.3
Industry
27.3
vs History
vs Industry
53
Median 3Y
-0.8
Median 5Y
2.1
Industry
2.6
vs History
63
vs Industry
24
Median 3Y
18
Median 5Y
23.8
Industry
8.1
Forward
11.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.6
vs History
vs Industry
Median 3Y
-1.6
Median 5Y
-3.3
Industry
4.3
Forward
-1.5
vs History
vs Industry
Median 3Y
-1.5
Median 5Y
-3.1
Industry
3.8
Forward
-1.4
vs History
vs Industry
2
Median 3Y
-3.2
Median 5Y
-3.9
Industry
6
vs History
vs Industry
3
Median 3Y
-3.2
Median 5Y
-3.9
Industry
3.8
vs History
69
vs Industry
10
Median 3Y
20.8
Median 5Y
21.9
Industry
4.8

Multiples Across Competitors

SIGHT Competitors Multiples
Gensight Biologics SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Gensight Biologics SA
PAR:SIGHT
31.5m EUR 13.4 -1 -1.2 -1.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 380 957.8 -177 666.1 -215 743.3 -213 281.4
US
Abbvie Inc
NYSE:ABBV
302.3B USD 5.4 59.5 14.9 22.9
US
Amgen Inc
NASDAQ:AMGN
160.6B USD 4.9 38 17.7 33.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.3B USD 11.9 -263.2 26.7 28
US
Gilead Sciences Inc
NASDAQ:GILD
118.3B USD 4.2 939 10.4 10.4
US
Epizyme Inc
F:EPE
94.1B EUR 1 884.6 -480.9 -523.7 -509.7
AU
CSL Ltd
ASX:CSL
138.5B AUD 6.1 34.3 21.1 26.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
90.4B USD 6.5 19.4 17.9 19.9
US
Seagen Inc
F:SGT
39.3B EUR 18.2 -55.7 -59.8 -54
NL
argenx SE
XBRU:ARGX
33.4B EUR 18.2 -127.9 -102.8 -74.9
P/E Multiple
Earnings Growth
FR
Gensight Biologics SA
PAR:SIGHT
Average P/E: 218
Negative Multiple: -1
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -177 666.1 N/A
US
Abbvie Inc
NYSE:ABBV
59.5
412%
US
Amgen Inc
NASDAQ:AMGN
38
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -263.2
42%
US
Gilead Sciences Inc
NASDAQ:GILD
939
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -480.9 N/A
AU
CSL Ltd
ASX:CSL
34.3
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -127.9 N/A
EV/EBITDA Multiple
EBITDA Growth
FR
Gensight Biologics SA
PAR:SIGHT
Average EV/EBITDA: 18.1
Negative Multiple: -1.2
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -215 743.3 N/A
US
Abbvie Inc
NYSE:ABBV
14.9
28%
US
Amgen Inc
NASDAQ:AMGN
17.7
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.7
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.4
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -523.7 N/A
AU
CSL Ltd
ASX:CSL
21.1
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.8 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -102.8 N/A
EV/EBIT Multiple
EBIT Growth
FR
Gensight Biologics SA
PAR:SIGHT
Average EV/EBIT: 23.5
Negative Multiple: -1.1
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -213 281.4 N/A
US
Abbvie Inc
NYSE:ABBV
22.9
88%
US
Amgen Inc
NASDAQ:AMGN
33.4
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.4
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -509.7 N/A
AU
CSL Ltd
ASX:CSL
26.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.9
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -74.9 N/A

See Also

Discover More
Back to Top